Screener

Eligibility screening

Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Sponsored by Turning Point Therapeutics, Inc.Study detailsClinicalTrials.gov

20 US sites in CA, CO, FL, GA +11

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.